Join

An Avidity-Based PD-L1 Antagonist Using Nanoparticle-Antibody Conjugates for Enhanced Immunotherapy

June 8, 2020
Cite this

Abstract

Upregulation of programmed death ligand 1 (PD-L1) allows cancer cells to evade antitumor immunity. Despite tremendous efforts in developing PD-1/PD-L1 immune checkpoint inhibitors (ICIs), clinical trials using such ICIs have shown inconsistent benefits. Here, we hypothesized that the ICI efficacy would be dictated by the binding strength of the inhibitor to the target proteins. To assess this, hyperbranched, multivalent poly(amidoamine) dendrimers were employed to prepare dendrimer–ICI conjugates (G7-aPD-L1). Binding kinetics measurements using SPR, BLI, and AFM revealed that G7-aPD-L1 exhibits significantly enhanced binding strength to PD-L1 proteins, compared to free aPD-L1. The binding avidity of G7-aPD-L1 was translated into in vitro efficiency and in vivo selectivity, as the conjugates improved the PD-L1 blockade effect and enhanced accumulation in tumor sites. Our results demonstrate that the dendrimer-mediated multivalent interaction substantially increases the binding avidity of the ICIs and thereby improves the antagonist effect, providing a novel platform for cancer immunotherapy.

Comparison between T Cell Exhaustion and T Cell Activity with working against cancer cells

Published

Nano Letters
Nano Letters Volume 20 Issue 7 journal cover

Cited by

This article is cited by 19 publications

  1. Poellmann, M. J., Bu, J., Liu, S., Wang, A. Z., Seyedin, S. N., Chandrasekharan, C., Hong, H., Kim, Y., Caster, J. M., & Hong, S. (2023). Nanotechnology and machine learning enable circulating tumor cells as a reliable biomarker for radiotherapy responses of gastrointestinal cancer patients. Biosensors & bioelectronics, 226, 115117. https://doi.org/10.1016/j.bios.2023.115117
  2. Wang, Q., Dong, Z., Lou, F., Yin, Y., Zhang, J., Wen, H., Lu, T., & Wang, Y. (2022). Phenylboronic ester-modified polymeric nanoparticles for promoting TRP2 peptide antigen delivery in cancer immunotherapy. Drug delivery, 29(1), 2029–2043. https://doi.org/10.1080/10717544.2022.2086941
  3. Dessale, M., Mengistu, G., & Mengist, H. M. (2022). Nanotechnology: A Promising Approach for Cancer Diagnosis, Therapeutics and Theragnosis. International journal of nanomedicine, 17, 3735–3749. https://doi.org/10.2147/IJN.S378074
  4. Yu, X., Fang, C., Zhang, K., & Su, C. (2022). Recent Advances in Nanoparticles-Based Platforms Targeting the PD-1/PD-L1 Pathway for Cancer Treatment. Pharmaceutics, 14(8), 1581. https://doi.org/10.3390/pharmaceutics14081581
  5. Rawding, P. A., Bu, J., Wang, J., Kim, D. W., Drelich, A. J., Kim, Y., & Hong, S. (2022). Dendrimers for cancer immunotherapy: Avidity-based drug delivery vehicles for effective anti-tumor immune response. Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology, 14(2), e1752. https://doi.org/10.1002/wnan.1752